David L Veenstra (David Veenstra)

ORCID

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 7

Top Venues

Future oncology (London, England)

Genetics in medicine : official journal of the American College of Medical Genetics

PharmacoEconomics

Cancer medicine

University of Washington

University of California San Francisco (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

University of Washington Jul 01 1999

United States

Professor :: Comparative Health Outcomes, Policy & Economics (CHOICE) Institute, Dept. of Pharmacy

Education History

University of California San Francisco

United States

PHD :: Pharmaceutical Chemistry

Publications

William Bruce Wong, Stacey Kowal, Tu My To, Achal Patel, David L Veenstra, Louis P Garrison, Meng Li
The value of the accelerated approval pathway: real-world outcomes associated with reducing the time between innovations. Future oncology (London, England) (2024)
William Bruce Wong, Stacey Kowal, Tu My To, Achal Patel, David L Veenstra, Louis P Garrison, Meng Li
The value of the accelerated approval pathway: real-world outcomes associated with reducing the time between innovations. Future oncology (London, England) (2024)
William Bruce Wong, Stacey Kowal, Tu My To, Achal Patel, David L Veenstra, Louis P Garrison, Meng Li
The value of the accelerated approval pathway: real-world outcomes associated with reducing the time between innovations. Future oncology (London, England) 20 (16) (2024)
Boya Guo, Sarah A Knerr, Tia L Kauffman, Kathleen F Mittendorf, Erin Keast, Marian J Gilmore, Heather Spencer Feigelson, Frances L Lynch, Kristin R Muessig, Sonia Okuyama, Jamilyn M Zepp, David L Veenstra, Li Hsu, Amanda I Phipps, Sara Lindström, Michael C Leo, Katrina A B Goddard, Benjamin S Wilfond, Beth Devine, null null
Risk management actions following genetic testing in the Cancer Health Assessments Reaching Many (CHARM) Study: A prospective cohort study. Cancer medicine (2023)
Woojung Lee, William Bruce Wong, Stacey Kowal, Louis P Garrison, David L Veenstra, Meng Li
Modeling the Ex Ante Clinical Real Option Value in an Innovative Therapeutic Area: ALK-Positive Non-Small-Cell Lung Cancer. PharmacoEconomics 40 (6) (2022)
Nathaniel Hendrix, Deirdre Weymann, Jagori Chatterjee, Devender S Dhanda, Anirban Basu, David L Veenstra, Josh J Carlson
Provider preferences for resolving uncertainty and avoiding harms in precision medicine: a discrete choice experiment. Personalized medicine 17 (5) (2020)
David L Veenstra, Gregory F Guzauskas, Josh Peterson, Dina A Hassen, Susan Snyder, Jing Hao, Marc S Williams
Cost-effectiveness of population genomic screening. Genetics in medicine : official journal of the American College of Medical Genetics 21 (12) (2019)

David L Veenstra.css-eqlu8i{font-size:small;padding-left:4px;} (David Veenstra)

Publication Activity (10 Years)

Top Topics

Top Venues

David L Veenstra (David Veenstra)